28.02.2022 13:00:00
|
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:
- A panel at the Cowen 42nd Annual Health Care Conference at 10:30 a.m. ET on Monday, March 7, 2022.
- A presentation followed by a fireside chat at the Barclays Global Healthcare Conference at 3:50 p.m. ET on Wednesday, March 16, 2022.
A live webcast of the Cowen panel and Barclays presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com
Tel 862.368.4464
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-301490859.html
SOURCE Syndax Pharmaceuticals, Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Syndax Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Syndax Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Syndax Pharmaceuticals Inc | 13,50 | -1,46% |